WebinarsNew
Deep DiveNew
Explore Business Standard
WebinarsNew
Deep DiveNew
Explore Business Standard
The revenue stands at ₹8,099.80 crore, reflecting a quarter-on-quarter *(QoQ) increase of 7.33 per cent from ₹7,546.40 crore. This corresponds to a year-on-year *(YoY) decline of 5.51 per cent.
Operating Profit stands at ₹861.40 crore, reflecting a quarter-on-quarter *(QoQ) increase of 34.59 per cent from ₹640.00 crore. This corresponds to a year-on-year *(YoY) decline of 60.37 per cent.
PBDT stands at ₹1,089.90 crore, reflecting a quarter-on-quarter *(QoQ) increase of 44.01 per cent from ₹756.80 crore. This corresponds to a year-on-year *(YoY) decline of 54.23 per cent.
Profit Before Tax stands at ₹553.30 crore, reflecting a quarter-on-quarter *(QoQ) increase of 177.07 per cent from ₹199.70 crore. This corresponds to a year-on-year *(YoY) decline of 70.96 per cent.
Net Profit stands at ₹435.60 crore, reflecting a quarter-on-quarter *(QoQ) increase of 96.84 per cent from ₹221.30 crore. This represents a 69.10 per cent year-on-year *(YoY) decline for the same year.
| Category | Q1 FY26-27 | Q1 FY25-26 | Change % | FY25-26 | FY24-25 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 8,099.80 | 8,572.10 | -5.51 | 33,700.20 | 32,643.90 | 3.24 |
| Expenses | 7,238.40 | 6,398.50 | 13.13 | 27,246.70 | 24,096.80 | 13.07 |
| Other Income | 355.50 | 290.50 | 22.38 | 1,371.80 | 1,119.00 | 22.59 |
| Operating Profit | 861.40 | 2,173.60 | -60.37 | 7,825.30 | 9,666.10 | -19.04 |
| Depreciation | 536.60 | 476.10 | 12.71 | 2,058.80 | 1,703.70 | 20.84 |
| Interest | 125.50 | 83.00 | 51.20 | 373.80 | 282.90 | 32.13 |
| Profit Before Tax | 553.30 | 1,905.00 | -70.96 | 5,392.70 | 7,679.50 | -29.78 |
| Tax | 117.70 | 495.10 | -76.23 | 1,394.50 | 2,258.10 | -38.24 |
| Net Profit | 435.60 | 1,409.90 | -69.10 | 4,157.60 | 5,725.20 | -27.38 |
| Category | Q1 FY26-27 | Q1 FY25-26 | Change % | FY25-26 | FY24-25 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 5,136.60 | 7,809.50 | -34.23 | 20,532.80 | 23,115.40 | -11.17 |
| Expenses | 4,687.70 | 3,972.50 | 18.00 | 16,615.40 | 15,733.60 | 5.60 |
| Other Income | 440.40 | 398.30 | 10.57 | 1,689.60 | 1,003.40 | 68.39 |
| Operating Profit | 4,012.10 | 6,709.00 | -40.20 | 5,607.00 | 8,385.20 | -33.13 |
| Depreciation | 317.70 | 279.80 | 13.55 | 1,207.40 | 1,039.40 | 16.16 |
| Interest | 73.10 | 19.20 | 280.73 | 148.30 | 109.90 | 34.94 |
| Profit Before Tax | 497.00 | 3,936.30 | -87.37 | 4,251.30 | 7,235.90 | -41.25 |
| Tax | 92.30 | 975.10 | -90.53 | 917.70 | 1,790.50 | -48.75 |
| Net Profit | 404.70 | 2,961.20 | -86.33 | 3,219.70 | 5,349.40 | -39.81 |
| Category | Q1 FY26-27 | Q4 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 8,099.80 | 7,546.40 | 7.33 |
| Expenses | 7,238.40 | 6,906.40 | 4.81 |
| Other Income | 355.50 | 480.00 | -25.94 |
| Operating Profit | 861.40 | 640.00 | 34.59 |
| Depreciation | 536.60 | 557.10 | -3.68 |
| Interest | 125.50 | 105.70 | 18.73 |
| Profit Before Tax | 553.30 | 199.70 | 177.07 |
| Tax | 117.70 | -21.60 | -644.91 |
| Net Profit | 435.60 | 221.30 | 96.84 |
| Category | Q1 FY26-27 | Q4 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 5,136.60 | 3,822.00 | 34.40 |
| Expenses | 4,687.70 | 4,200.80 | 11.59 |
| Other Income | 440.40 | 567.20 | -22.36 |
| Operating Profit | 4,012.10 | 2,739.30 | 46.46 |
| Depreciation | 317.70 | 318.50 | -0.25 |
| Interest | 73.10 | 54.30 | 34.62 |
| Profit Before Tax | 497.00 | -305.50 | -262.68 |
| Tax | 92.30 | -86.10 | -207.20 |
| Net Profit | 404.70 | -219.40 | -284.46 |
Data not available.
| Company | 1 Day | 1 Week | 1 Month | 3 Months | 6 Month | 1 Year |
|---|---|---|---|---|---|---|
| Dr Reddy's Labs | -0.33% | -0.25% | -1.74% | -9.72% | -6.16% | -4.89% |
| Cipla | -0.75% | -0.82% | 0.59% | 1.64% | 7.48% | -7.31% |
| Zydus Lifesci. | -2.81% | -3.39% | -0.58% | 15.01% | 25.27% | 15.55% |
| Lupin | -1.15% | -1.89% | -9.82% | -0.80% | 0.39% | 13.48% |
| Mankind Pharma | 0.08% | -0.21% | -5.69% | -3.06% | 16.62% | -2.02% |
| Laurus Labs | -1.42% | -2.42% | 16.40% | 36.76% | 74.90% | 109.74% |
| Aurobindo Pharma | 0.08% | 0.97% | 6.24% | 10.41% | 42.96% | 52.11% |
